Prognostic Value of Circulating Tumor DNA for Minimal Residual Disease Detection in Ovarian Cancer: A Systematic Review and Meta-analysis
Our findings suggest that ctDNA is a novel instrument for MRD detection, and its presence serves as a potent prognostic indicator for recurrence and mortality in ovarian cancer. These results support integrating ctDNA into clinical trial designs and highlight its potential for risk-adapted surveillance and treatment strategies.
Authors
- Mariana Carvalho Gouveia (ORCID: https://orcid.org/0000-0001-8194-7594)
- Ana Veneziani (ORCID: https://orcid.org/0000-0003-3980-034X)
- Pedro Robson Costa Passos (ORCID: https://orcid.org/0009-0007-9049-0996)
- Mariana Macambira Noronha (ORCID: https://orcid.org/0000-0003-0889-7425)
- Valbert Oliveira Costa Filho (ORCID: https://orcid.org/0009-0003-2864-0966)
- Rafael Lara Nohmi
- Otávio Al-Alam
- Erick Saldanha
- Luiz Felipe Costa Almeida
- Luís Inácio Falcão da Silva
Institutions
- Universidade Federal Fluminense (BR)
- Universidade Federal do Ceará (BR)
- Princess Margaret Cancer Centre (CA)
- Brf (Brazil) (BR)
- Universidade Federal de Santa Maria (BR)
- Hospital Moinhos de Vento (BR)
- Hospital Universitário de Santa Maria (BR)
Publication Details
- Journal
- Critical Reviews in Oncology/Hematology
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.critrevonc.2026.105300
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00